Wikipedia -WSS

Wikipedia

author：knowledge 2025-09-30 00:36:24 - browse：14468

A sign of pharmaceutical company Bayer in front of a blossomed tree — coverage from STAT — INA FASSBENDER/AFP via Getty Images

More hopeful news on the menopause front: Bayer announced on Monday encouraging results in two Phase 3 trials for its non-hormonal drug candidate, elinzanetant, meant to treat hot flashes. The results follow the recent market launch of Veozah, Astellas Pharma’s groundbreaking non-hormonal treatment for hot flashes, which was approved by the U.S. Food and Drug Administration last spring and received approval in the U.K., under the name Veozah, in December.

Elinzanetant is a neurokinin-1 and 3 receptor antagonist, and works by calming down the estrogen receptors in the brain that become hyperactive around menopause, causing hot flashes. The drug, a pill administered once a day, was shown to reduce both the frequency and intensity of hot flashes, and also met the secondary endpoints for improving sleep and quality of life, according to JoAnn Pinkerton, professor of obstetrics and gynecology and director of the Midlife Health at UVA Health, who is a clinical investigator for Bayer’s drug candidate.

Pinkerton said she was excited to see the broader quality of life improvements through elinzanetant: “Women have more than just hot flashes — it’s actually more about hot flushes, sweats, fatigue, lack of sleep and some of the mood changes that go on during [menopause].”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： The tragedy of Johnson & Johnson’s Covid vaccine

WSS

Steward Health Care files for bankruptcy

Prior authorization will have to move faster under new Biden rule

First recipient of genetically engineered pig kidney has died

After gene therapy, two congenitally deaf children hear for the first time

Use wet bulb globe temperature, not heat index, to protect workers

Dewpoint Therapeutics lays off staff after losing partnerships

focus

Wikipedia

explore

BioMarin wins approval for gene therapy to treat hemophilia A

EU regulator recommends expanding Mounjaro approval to obesity

Medicare details structure of new drug price negotiation program

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Moonlake's readout produced a cash windfall. Risks remain

Making AI in medicine accessible to smaller, and rural hospitals

Jerome Adams on the need for new antivirals for Covid

Elizabeth Holmes banned from government health programs

Affirmative action in medical school literally saved lives

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

hotspot

How to improve immunocompromised access to mAb treatments

Medicare says breakthrough device reimbursement rule to come by summer

My yearlong odyssey to get my son’s ADHD medication covered

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Humana cuts profit projections as Medicare Advantage costs soar

Brain worms: The science behind RFK Jr.'s parasitic infection

leisure time

knowledge

knowledge

hotspot